 src-Family Kinases
"src-Family Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A PROTEIN-TYROSINE KINASE family that was originally identified by homology to the Rous sarcoma virus ONCOGENE PROTEIN PP60(V-SRC). They interact with a variety of cell-surface receptors and participate in intracellular signal transduction pathways. Oncogenic forms of src-family kinases can occur through altered regulation or expression of the endogenous protein and by virally encoded src (v-src) genes.
| Descriptor ID |
D019061
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.800
|
| Concept/Terms |
src-Family Kinases- src-Family Kinases
- src Family Kinases
- src-Family Tyrosine Kinases
- Tyrosine Kinases, src-Family
- src Family Tyrosine Kinases
- src Tyrosine Kinases
- Kinases, src Tyrosine
- Tyrosine Kinases, src
- Protein-Tyrosine Kinases, src
- Kinases, src Protein-Tyrosine
- src Protein-Tyrosine Kinases
- src Kinases
- Kinases, src
|
Below are MeSH descriptors whose meaning is more general than "src-Family Kinases".
Below are MeSH descriptors whose meaning is more specific than "src-Family Kinases".
This graph shows the total number of publications written about "src-Family Kinases" by people in this website by year, and whether "src-Family Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 | | 1997 | 1 | 0 | 1 | | 2001 | 1 | 0 | 1 | | 2002 | 1 | 1 | 2 | | 2003 | 1 | 0 | 1 | | 2004 | 0 | 3 | 3 | | 2005 | 2 | 1 | 3 | | 2006 | 0 | 3 | 3 | | 2007 | 0 | 2 | 2 | | 2008 | 0 | 2 | 2 | | 2009 | 2 | 0 | 2 | | 2010 | 1 | 2 | 3 | | 2011 | 1 | 2 | 3 | | 2012 | 3 | 3 | 6 | | 2013 | 2 | 1 | 3 | | 2014 | 3 | 2 | 5 | | 2015 | 2 | 0 | 2 | | 2016 | 3 | 4 | 7 | | 2017 | 1 | 0 | 1 | | 2018 | 1 | 1 | 2 | | 2019 | 1 | 0 | 1 | | 2022 | 0 | 1 | 1 | | 2023 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "src-Family Kinases" by people in Profiles.
-
Bolf EL, Beadnell TC, Rose MM, D'Alessandro A, Nemkov T, Hansen KC, Schweppe RE. Dasatinib and Trametinib Promote Anti-Tumor Metabolic Activity. Cells. 2023 05 12; 12(10).
-
Ahangari F, Becker C, Foster DG, Chioccioli M, Nelson M, Beke K, Wang X, Justet A, Adams T, Readhead B, Meador C, Correll K, Lili LN, Roybal HM, Rose KA, Ding S, Barnthaler T, Briones N, DeIuliis G, Schupp JC, Li Q, Omote N, Aschner Y, Sharma L, Kopf KW, Magnusson B, Hicks R, Backmark A, Dela Cruz CS, Rosas I, Cousens LP, Dudley JT, Kaminski N, Downey GP. Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis. Am J Respir Crit Care Med. 2022 12 15; 206(12):1463-1479.
-
Hazegh K, Fang F, Kelly K, Sinchar D, Wang L, Zuchelkowski BE, Ufelle AC, Esparza O, Davizon-Castillo P, Page GP, Kanias T. Erythrocyte mitogen-activated protein kinases mediate hemolytic events under osmotic and oxidative stress and in hemolytic diseases. Cell Signal. 2022 11; 99:110450.
-
Broeckel R, Sarkar S, May NA, Totonchy J, Kreklywich CN, Smith P, Graves L, DeFilippis VR, Heise MT, Morrison TE, Moorman N, Streblow DN. Src Family Kinase Inhibitors Block Translation of Alphavirus Subgenomic mRNAs. Antimicrob Agents Chemother. 2019 04; 63(4).
-
Kessler BE, Mishall KM, Kellett MD, Clark EG, Pugazhenthi U, Pozdeyev N, Kim J, Tan AC, Schweppe RE. Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis. Oncogene. 2019 04; 38(14):2565-2579.
-
Andreotti AH, Joseph RE, Conley JM, Iwasa J, Berg LJ. Multidomain Control Over TEC Kinase Activation State Tunes the T Cell Response. Annu Rev Immunol. 2018 04 26; 36:549-578.
-
Scott AJ, Song EK, Bagby S, Purkey A, McCarter M, Gajdos C, Quackenbush KS, Cross B, Pitts TM, Tan AC, Eckhardt SG, Fenton H, Arcaroli J, Messersmith WA. Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model. PLoS One. 2017; 12(11):e0187173.
-
Myklebust JH, Brody J, Kohrt HE, Kolstad A, Czerwinski DK, W?lchli S, Green MR, Tr?en G, Liest?l K, Beiske K, Houot R, Delabie J, Alizadeh AA, Irish JM, Levy R. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. Blood. 2017 02 09; 129(6):759-770.
-
Nakachi I, Helfrich BA, Spillman MA, Mickler EA, Olson CJ, Rice JL, Coldren CD, Heasley LE, Geraci MW, Stearman RS. PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines. Clin Transl Sci. 2016 12; 9(6):293-301.
-
Gari HH, DeGala GD, Ray R, Lucia MS, Lambert JR. PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion. Cancer Lett. 2016 10 01; 380(2):505-512.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|